PDEs1-5 activity and expression in tissues of cirrhotic rats reveal a role for aortic PDE3 in NO desensitization

International Journal of Experimental Pathology

Volumn 90, Issue 6, 2009, Pages 605-614

  Tahseldar Roumieh, Rima ^a,b   Keravis, Thérèse ^a   Maarouf, Suha ^b   Justiniano, Hélène ^a   Sabra, Ramzi ^b   Lugnier, Claire ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Bile duct ligation; CAMP; CGMP; DMPPO PDE5 inhibitor; PDE1A; PDE3 upregulation

Indexed keywords

CILOSTAMIDE; CYCLIC GMP; NITRIC OXIDE; PHOSPHODIESTERASE 3A; PHOSPHODIESTERASE 3B; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V; SPLEEN EXONUCLEASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BILE DUCT LIGATION; BLOOD VESSEL TONE; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; DESENSITIZATION; ENZYME ACTIVITY; KIDNEY FUNCTION; LIVER CIRRHOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SODIUM RETENTION; VASCULAR TISSUE;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; ANIMALS; AORTA; BILE DUCTS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; ISOENZYMES; KIDNEY; KIDNEY CORTEX; LIGATION; LIVER CIRRHOSIS; MESENTERIC ARTERIES; NITRIC OXIDE DONORS; PHOSPHODIESTERASE INHIBITORS; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 71449090673     PISSN: 09599673     EISSN: 13652613     Source Type: Journal    
DOI: 10.1111/j.1365-2613.2009.00678.x     Document Type: Article

References (46)

1. Ahloulay M., Bankir L., Lugnier C. et al. (2005) Cyclic AMP-phosphodiesterases inhibitor improves sodium excretion in rats with cirrhosis and ascites. Liver Int. 25, 403 409.
2. Angeli P., Jimenez W., Veggian R. et al. (2000) Increased activity of guanosine 3′-5′-cyclic monophosphate phosphodiesterase in the renal tissue of cirrhotic rats with ascites. Hepatology 31, 304 310.
3. Atucha N.M., Nadal F.J., Iyu D. et al. (2005) Role of vascular nitric oxide in experimental liver cirrhosis. Curr. Vasc. Pharmacol. 3, 81 85.
4. Bernardi M. Di Marco C., Trevisani F. et al. (1993) Renal sodium retention during upright posture in preascitic cirrhosis. Gastroenterology 105, 188 193.
5. Blendis L., Wong F. (2001) The hyperdynamic circulation in cirrhosis: an overview. Pharmacol. Ther. 89, 221 231.
6. Brond L., Hadrup N., Salling N. et al. (2004) Uncoupling of vasopressin signaling in collecting ducts from rats with CBL-induced liver cirrhosis. Am. J. Physiol. Renal. Physiol. 287, F806 F815.
7. Corbin J.D. (2004) Mechanisms of action of PDE5 inhibition in erectile dysfunction. Int. J. Impot. Res. 16 (Suppl. I S4 S7.
8. Coste H. Grondin P. (1995) Characterization of a novel potent and specific inhibitor of type V phosphodiesterase. Biochem. Pharmacol. 50, 1577 1585.
9. Dousa T.P. (1999) Cyclic-3′,5′-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney. Kidney Int. 55, 29 62.
10. Eckly A.E. Lugnier C. (1994) Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway. Br. J. Pharmacol. 113, 445 450.
11. Eckly-Michel A.E., Le Bec A., Lugnier C. (1997) Chelerythrine, a protein kinase C inhibitor, interacts with cylic nucleotide phosphodiesterases. Eur. J. Pharmacol. 324, 85 88.
12. Favot L., Keravis T., Lugnier C. (2004) Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4. Thromb. Haemost. 92, 634 645.
13. Haneda M., Kikkawa R., Maeda S. et al. (1991) Dual mechanism of angiotensin II inhibits ANP-induced mesangial cGMP accumulation. Kidney Int. 40, 188 194.
14. Jackson B.A., Edwards R.M., Dousa T.P. (1980) Measurements of cyclic AMP and cyclic GMP phosphodiesterase activity in isolated tubular segments. Kidney Int. 18, 512 518.
15. Jackson E.K., Mi Z., Carcillo J.A., Gillespie D.G., Dubey R.K. (1997) Phosphodiesterases in the rat renal vasculature. J. Cardiovasc. Pharmacol. 30, 798 801.
16. Keravis T. Lugnier C. (2007) Cyclic nucleotide phosphodiesterase (PDE) superfamily and smooth muscle signaling. In : New Frontiers in Smooth Muscle Biology and Physiology, pp. 269 289 (ed. J.-P. Savineau Trivandrum, Kerala, India : Transworld Research Network.
17. Keravis T., Thaseldar-Roumié R., Lugnier C. (2005) Assessment of phosphodiesterase isozyme contribution in cell and tissue extracts. Methods Mol. Biol. 307, 63 74.
18. Keravis T., Silva A.P., Favot L., Lugnier C. (2006) Endothelial PDEs and angiogenesis. In : Cyclic Nucleotide Phosphodiesterases in Health and Disease, pp. 417 439 (eds J. Beavo, S. Francis, M. Houslay Boca Raton, FL : CRC Press.
19. Kessler T. Lugnier C. (1995) Rolipram increases cyclic GMP content in l-arginine-treated cultured bovine aortic endothelial cells. Eur. J. Pharmacol. 290, 163 167.
20. Kim D., Rybalkin S.D., Pi X. et al. (2001) Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation 104, 2338 2343.
21. Komas N., Lugnier C., Andriantsitohaina R., Stoclet J.C. (1991a) Characterisation of cyclic nucleotide phosphodiesterases from rat mesenteric artery. Eur. J. Pharmacol. 208, 85 87.
22. Komas N., Lugnier C., Stoclet J.C. (1991b) Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors. Br. J. Pharmacol. 104, 495 503.
23. Laffi G., La Villa G., Pinzani M. et al. (1984) Vasoactive factors in the mechanism of renal sodium handling in cirrhotics: the effect of acute plasma expansion. Pharmacol. Res. Commun. 16, 613 635.
24. Lee E.Y. Humphreys M.H. (1996) Phosphodiesterase activity as a mediator of renal resistance to ANP in pathological salt retention. Am. J. Physiol. Renal. Physiol. 271, F3 F6.
25. Levy M. (1997) Atrial natriuretic peptide: renal effects in cirrhosis of the liver. Semin. Nephrol. 17, 520 529. (Pubitemid 27465010)
26. Liu H. Maurice D.H. (1998) Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP. Br. J. Pharmacol. 125, 1501 1510.
27. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265 275.
28. Lugnier C. (2006) Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol. Ther. 109, 366 398.
29. Lugnier C. Komas N. (1993) Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: role in vasodilatation. Eur. Heart J. 14 (Suppl. I 14 18.
30. Lugnier C., Schoeffter P., Le Bec A., Strouthou E., Stoclet J.C. (1986) Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem. Pharmacol. 35, 1743 1751.
31. Ni X., Cheng Y., Cao L., Gardner D.G., Humphreys M.H. (1996) Mechanisms contributing to renal resistance to atrial natriuretic peptide in rats with common bile-duct ligation. J. Am. Soc. Nephrol. 7, 2110 2118.
32. Ni X.P., Safai M., Gardner D.G., Humphreys M.H. (2001) Increased cGMP phosphodiesterase activity mediates renal resistance to ANP in rats with bile duct ligation. Kidney Int. 59, 1264 1273.
33. Orallo F., Alvarez E., Basaran H., Lugnier C. (2004) Comparative study of the vasorelaxant activity, superoxide-scavenging ability and cyclic nucleotide phosphodiesterase-inhibitory effects of hesperetin and hesperidin. Naunyn Schmiedebergs Arch. Pharmacol. 370, 452 463.
34. Pauvert O., Lugnier C., Keravis T., Marthan R., Rousseau E., Savineau J.P. (2003) Effect of sildenafil on cyclic nucleotide phosphodiesterase activity, vascular tone and calcium signaling in rat pulmonary artery. Br. J. Pharmacol. 139, 513 522.
35. Schoeffter P., Lugnier C., Demesy-Waeldele F., Stoclet J.C. (1987) Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. A study with selective inhibitors. Biochem. Pharmacol. 36, 3965 3972.
36. Schrier R.W., Arroyo V., Bernardi M., Epstein M., Henriksen J.H., Rodes J. (1988) Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8, 1151 1157.
37. Schroeder E.T., Eich R.H., Smulyan H., Gould A.B., Gabuzda G.J. (1970) Plasma renin level in hepatic cirrhosis. Relation to functional renal failure. Am. J. Med. 49, 186 191.
38. Stoclet J.C., Keravis T., Lugnier C. (1995) Cyclic nucleotide phosphodiesterase as therapeutic targets in cardiovascular diseases. Expert Opin. Investig. Drugs 4, 1081 1100.
39. Tahseldar-Roumieh R., Ghali-Ghoul R., Lugnier C., Sabra R. (2006) Effect of phosphodiesterase 5 inhibition on the alteration in vascular smooth muscle sensitivity and renal function in rats with liver cirrhosis. Am. J. Physiol. Heart Circ. Physiol. 290, H481 H488.
40. Takimoto E., Champion H.C., Li M. et al. (2005) Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat. Med. 1, 214 222.
41. Torres V.E., Hui Y.S., Shah S.V., Northrup T.E., Dousa T.P. (1978) Cyclic nucleotide phosphodiesterases in glomeruli of rat renal cortex. Kidney Int. 14, 444 451.
42. Valentin J.P., Qiu C., Muldowney W.P., Ying W.Z., Gardner D.G., Humphreys M.H. (1992) Cellular basis for blunted volume expansion natriuresis in experimental nephrotic syndrome. J. Clin. Invest. 90, 1302 1312.
43. Valentin J.P., Ying W.Z., Sechi L.A. et al. (1996) Phosphodiesterase inhibitors correct resistance to natriuretic peptides in rats with Heymann nephritis. J. Am. Soc. Nephrol. 7, 582 593.
44. Wiest R. Groszmann R.J. (2002) The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 35, 478 491.
45. Yamaki M., McIntyre S., Rassier M.E., Schwartz J.H., Dousa T.P. (1992) Cyclic 3′, 5′-nucleotide diesterases in dynamics of cAMP and cGMP in rat collecting duct cells. Am. J. Physiol. Renal. Physiol. 262, F957 F964.
46. Yoshida I., Takeda S., Homma S., Kusano E., Asano Y. (1997) Localization of low-Km cAMP phosphodiesterase in rat nephron segments. Kidney Blood Press. Res. 20, 307 311.